Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

PURPOSE The major mechanism of resistance to alkylnitrosourea therapy is the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), which removes chlorethylation or methylation damage from the O6-position of guanine. O6-benzylguanine (O6-BG) is an AGT substrate that inhibits AGT by suicide inactivation. We conducted a phase I trial to define the presurgical dose required for depletion of tumor AGT activity in patients with malignant glioma. MATERIALS AND METHODS Patients were to be treated 18 hours before craniotomy with intravenous doses that ranged between 40 and 100 mg/m2 given over 1 hour. Resected tumor was snap-frozen in liquid nitrogen and AGT activity analyzed by high-pressure liquid chromatography (HPLC). Up to 13 patients were treated at a specific dose of O6-BG, with a target end point of > or = 11 of 13 patients with undetectable tumor AGT levels (< 10 fmol/mg protein). RESULTS Thirty patients with malignant gliomas were enrolled, with 11 of 11 patients treated at 100 mg/m2 O6-BG demonstrating tumor AGT levels less than 10 fmol/mg protein. No toxicity was noted in any patient treated. CONCLUSION These results indicate that 100 mg/m2 of O6-BG can maintain tumor AGT levels less than 10 fmol/mg protein for at least 18 hours after treatment, a time interval in which bis(2-chloroethyl)nitrosourea (BCNU)-induced chloroethyl adducts are fully converted into interstrand cross-links. A 100-mg/m2 dose of O6-BG will be used in combination with BCNU in another phase I trial designed to determine the maximal-tolerated dose of BCNU.

[1]  P. Kleihues,et al.  O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. , 1989, Journal of neurosurgery.

[2]  M. Dolan,et al.  O6-benzylguanine and its role in chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  W. Bodell,et al.  Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1987, Carcinogenesis.

[4]  M. Dolan,et al.  Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. , 1993, Biochemistry.

[5]  M. Dolan,et al.  Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.

[6]  D. Ludlum.  DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. , 1990, Mutation research.

[7]  T. Brent,et al.  Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. , 1997, British Journal of Cancer.

[8]  D. Yarosh,et al.  The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. , 1985, Mutation research.

[9]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[10]  K. Paigen,et al.  A simple, rapid, and sensitive DNA assay procedure. , 1980, Analytical biochemistry.

[11]  M. Dolan,et al.  Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. , 1985, Biochemical and biophysical research communications.

[12]  M. Dolan,et al.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Gerson,et al.  Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. , 1988, Cancer research.

[14]  W. Shapiro.  Therapy of adult malignant brain tumors: what have the clinical trials taught us? , 1986, Seminars in oncology.

[15]  B. Kaina,et al.  Regulation of repair of alkylation damage in mammalian genomes. , 1993, Progress in nucleic acid research and molecular biology.

[16]  P. Kleihues,et al.  O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. , 1984, Carcinogenesis.

[17]  K. Kohn,et al.  DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Levin.  Chemotherapy of primary brain tumors. , 1985, Neurologic clinics.

[19]  M. Dolan,et al.  Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. , 1986, Cancer research.

[20]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.

[21]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[22]  M. Prados,et al.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.

[23]  M. Dolan,et al.  Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme , 1992 .

[24]  T. Byers,et al.  Repair of DNA containing O6‐alkylguanine , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Dolan,et al.  Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. , 1990, Cancer communications.

[26]  M. Dolan,et al.  Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. , 1992, Cancer research.

[27]  M. Dolan,et al.  Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.

[28]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[29]  L. Erickson,et al.  Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. , 1984, Carcinogenesis.

[30]  R. Day,et al.  Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base. , 1986, Cancer research.

[31]  A. Pegg,et al.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.